html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

PapersPMID:28446297

[Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].

Zhongguo shi yan xue ye xue za zhi2017The record ↗

methylcob(III)alamin

no difference foundProgression-free survival

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →

No detected effect on progression-free survival
very limited
“Neither PFS nor OS was significantly different between HDIME group and control group(P>0.05).”
Study
RCT
Dose studied
high-dose intravenous mecobalamin, dose not stated in the abstract, added to bortezomib-based chemotherapy
Population
65 newly diagnosed multiple myeloma patients receiving bortezomib-based chemotherapy in both arms

Study record

Design: randomised controlled trial
Species: human
Population: newly diagnosed multiple myeloma patients receiving bortezomib
Participants: 65
Comparator: no treatment
Duration: not reported
Endpoints measured: 11